What is Positron?
Positron operates at the intersection of advanced molecular imaging and clinical cardiology. The company is recognized for its development of high-precision systems, most notably the NeuSight PET-CT, which is engineered to optimize cardiac diagnostics. By focusing on reducing scan times and enhancing image accuracy, Positron addresses key pain points in patient care and clinical efficiency. Its market position is defined by a commitment to technological innovation, providing healthcare providers with the tools necessary to improve diagnostic outcomes in complex cardiac cases.
How much funding has Positron raised?
Positron has raised a total of $305.1M across 3 funding rounds:
Seed
$23.5M
Series A
$51.6M
Series B
$230M
Seed (2025): $23.5M with participation from Atreides Management, Valor Equity Partners, and Flume Ventures
Series A (2025): $51.6M led by Atreides Management, Flume Ventures, Valor Equity Partners, DFJ Growth, Unless, and 1517 Fund I
Series B (2026): $230M supported by Jump Trading, Valor Equity Partners, Flume Ventures, DFJ Growth, and Unless
Key Investors in Positron
Valor Equity Partners
A Chicago-based firm established in 2001 that provides comprehensive financial services and strategic capital to businesses across various growth stages.
Flume Ventures
A network of seasoned operators and founders that partners with visionary entrepreneurs to scale category-defining technology businesses through mentorship and strategic guidance.
DFJ Growth
A global venture capital firm founded in 2005 that specializes in providing growth-stage capital to technology companies poised for market leadership.
What's next for Positron?
With the infusion of this latest capital, Positron is well-positioned to accelerate its commercial expansion and deepen its R&D capabilities. The company's strategic roadmap likely involves scaling its manufacturing capacity to meet the growing demand for PET-CT solutions while simultaneously investing in software enhancements that leverage its existing hardware infrastructure. As the firm moves into this next phase of growth, the focus will remain on solidifying its footprint in the global healthcare market and establishing the NeuSight platform as a standard of care in cardiac imaging. The continued support from its diverse investor base provides the necessary runway to navigate the complexities of the medical device industry and drive long-term value creation.
See full Positron company page
